TY - JOUR
T1 - Nuclear factor-κ B repression in antiinflammation and immunosuppression by glucocorticoids
AU - Van Der Burg, Bart
AU - Liden, Johan
AU - Okret, Sam
AU - Delaunay, Franck
AU - Wissink, Sacha
AU - Van Der Saag, Paul T.
AU - Gustafsson, Jan Åke
N1 - Funding Information:
This work was supported by grants from the Netherlands Asthma Foundation, the Swedish Medical Research Council, and the European Community.
PY - 1997
Y1 - 1997
N2 - The transcription factor nuclear factor-κB (NF-κB) directs transcription of a large number of key molecules in immunological and inflammatory responses. The recently discovered inhibition of transcriptional activity of this factor by the activated glucocorticoid receptor (GR) provides a molecular basis for the potent antiinflammatory and immunosuppressive properties of glucocorticoids. This repressive activity of the GR can function independently of transcriptional activity. Because it has been shown that certain steroid receptor ligands can differentially address transactivation and transrepression functions, it may be possible to develop ligands that specifically suppress NF-κB activity and, as a result, are more efficient in treatment of a variety of important chronic inflammatory diseases with less severe side effects than those of currently available drugs.
AB - The transcription factor nuclear factor-κB (NF-κB) directs transcription of a large number of key molecules in immunological and inflammatory responses. The recently discovered inhibition of transcriptional activity of this factor by the activated glucocorticoid receptor (GR) provides a molecular basis for the potent antiinflammatory and immunosuppressive properties of glucocorticoids. This repressive activity of the GR can function independently of transcriptional activity. Because it has been shown that certain steroid receptor ligands can differentially address transactivation and transrepression functions, it may be possible to develop ligands that specifically suppress NF-κB activity and, as a result, are more efficient in treatment of a variety of important chronic inflammatory diseases with less severe side effects than those of currently available drugs.
UR - http://www.scopus.com/inward/record.url?scp=0030988726&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030988726&partnerID=8YFLogxK
U2 - 10.1016/S1043-2760(97)00006-4
DO - 10.1016/S1043-2760(97)00006-4
M3 - Review article
C2 - 18406801
AN - SCOPUS:0030988726
VL - 8
SP - 152
EP - 157
JO - Trends in Endocrinology and Metabolism
JF - Trends in Endocrinology and Metabolism
SN - 1043-2760
IS - 4
ER -